Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey

Clinicopathological characteristics of de novo and secondary myeloid sarcoma: A monocentric retrospective study

“…the predilection for the last decades of life. 1,6,8,9,11,13,14 While most studies also show predilection for males, in our cohort both sexes were almost equally represented both in de novo and secondary MS. 6,8,9,11,13,14 This difference in M/F-ratio might possibly be explained by the size of the investigated cohorts in the different studies. 1,8,9,11,[13][14][15] Most frequent localizations were skin and lymph node.…”

“…The high incidence of skin and lymph node involvement is consistent with other reviews and studies. 1,3,4,[6][7][8][9]11,[13][14][15] Clinical symptoms were very heterogeneous, although local swellings or masses, local pain/pressure, and neurological symptoms were commonly seen.…”

“…extramedullary AML, extramedullary myeloid tumor, granulocytic sarcoma, or chloroma. 1,[3][4][5][6] MS can present as an isolated disease without concomitant bone marrow (BM) involvement in patients without a history of AML, myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), or MDS/MPN. MS can also be present at an initial diagnosis of AML, as a manifestation of relapse in a patient with previously diagnosed AML, or as a progression of a prior MDS, MPN, or MDS/MPN.…”

“…The skin, lymph nodes, gastrointestinal tract, bones, soft tissue, and testes are more frequently affected; however, any site of the body can be involved. 1,3,4,6,7,9 The diagnosis of MS can be challenging especially in patients without a history of concurrent AML, MDS, MPN or MDS/MPN. The diagnostic workup requires microscopic and immunohistochemical analysis of fresh tissue from the MS lesion.…”

Long-Lasting Remission in De Novo Breast Myeloid Sarcoma Treated with Decitabine and Radiotherapy

“…The emerging employment of 18 F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography ( 18 F-FDG-PET/CT) has significantly improved the staging of disease as well as the assessment of treatment response [2,7]. While the younger and fitter patients can be candidate for AML-like chemotherapy, for elderly patients a standard therapeutic approach is still lacking [2,8]. Hypomethylating agents, such as azacytidine and decitabine, are currently employed in elderly AML patients, but their role in MS remains unexplored.…”